Home News & Events Press releases Press releases Category AcquisitionsAwardsCorporate earningsESGInvestor conferencesLeadershipTechnologyWhitepaper Year 20252024202320222021202020192018201720162015 In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events Webinars Workshops Webinars Social media Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media What’s happening in ICON ICON Plc While cardiovascular outcome trials are critical to demonstrating clinical value, they can also be complex and costly. Among the most challenging aspects are the people involved, from patients to investigators and commit... 16 Dec View post View webpage ICON Plc Continuing our series of articles discussing managing risk for medical devices, ICON’s regulatory expert Jeremy Tinkler turns his focus on the biological risk estimate and looks into the logical basis for the use of comp... 16 Dec View post View webpage ICON Plc The key to estimating biological risk in medical devices is establishing a good comparison. However, identifying the right comparison can be challenging. In the latest blog in our managing risk for medical devices series... 16 Dec 1 View post View webpage ICON Plc Our Creative & Digital Services and Global Medical Communications teams have been honoured for the ISMPP Academy Poster with an Rx Club Award of Excellence in the Posters/Display category. Congratulations for delivering ... 16 Dec 2 View post ICON Plc There is great excitement following the announcements by the FDA and EMA around streamlining the biosimilar trial process. They promise to reduce the burden on developers and therefore increase the number of more afford... 16 Dec View post View webpage ICON Plc 2025 has seen both the EMA and the FDA publish new position papers and opinions on streamlining the trial process for biosimilars. On the surface, reducing reliance on comparative efficacy trials has the potential to sav... 16 Dec 1 View post View webpage ICON Plc Do you know the difference between decision trees and random forests? Learn about AI models for SaMDs in our new whitepaper. Download it now to learn best practices for model and data selection. https://ow.ly/nI8g50XAzbq 16 Dec 1 View post View webpage ICON Plc For medical device developers selecting the right AI model and data is crucial to capitalise on this powerful technology. Our new whitepaper explains best practices for AI-enabled devices. Learn about AI models, datase... 16 Dec View post View webpage ICON Plc Yao Zhong's career in clinical development spans two decades and multiple leadership roles across the industry. When the opportunity came to return to ICON and lead our newly integrated China business, he recognised the ... 16 Dec View post View webpage ICON Plc Zhong Yao's career in clinical development spans two decades and multiple leadership roles across the industry. When the opportunity came to return to ICON and lead our newly integrated China business, he recognised the ... 16 Dec 1 View post View webpage ICON Plc In a fast-moving market like healthcare, speed matters. Metys®, from Symphony Health, an ICON plc company, delivers weekly insights up to 3 days faster than other platforms – so you can respond to competitive shifts wi... 15 Dec 2 View post View webpage ICON Plc How do you go from a meaningful aspect of health to a validated endpoint? Download our whitepaper for a step-by-step guide on a structured approach to deploying digital endpoints: 1. Define the Concept of Interest 2. Id... 15 Dec View post View webpage
